Team

CEO

Graduate of the MIT Media Lab. Recipient of the inaugural Minsky Fellowship for prominent AI researchers. Previously a Pilot and Major in the Air Force, with a track record of managing over $100M and 20 people across major R&D projects.

CSO

Derrick Miyao is a pioneer in robotic synthesis and automated assays. Spent 20 years at Neurocrine, where he built two systems that have made >1M compounds.

Chief Innovation Officer

Associate Professor at the MIT Media Lab. Inventor of 103 issued U.S. patents and a member of the USPTO Investors Hall of Fame. Co-Founder of successful companies, including DeepCure, E-Ink, Gen9, Kovio and IgC Bio.

COO

Jeff Martin is a seasoned veteran in the life science technology space having served in entrepreneurial, leadership, commercial and technical roles at several organizations. Most recently he was co-founder and CEO of Lab Sync, a venture studio, where he was awarded 2024 CEO of the Year by CEO Monthly.

CTO

David Dambman has over 20 years of experience building teams, developing technology, and bringing products to market. As CTO of Biosero, David was responsible for the development of their automation scheduling and orchestration software products, as well as the design, build, and deployment of hundreds of automation platforms globally.

Director of Automation

Luke spearheaded large-scale automation and software projects at DeepCure and Neurocrine, enhancing the efficiency of early-stage drug discovery functions in automated small molecule synthesis, sample management, and screening.

Director of Chemistry

Heather L. Osswald is an expert in automated chemistry, having developed platforms for rapid chemical synthesis and lead compound identification in preclinical discovery. She earned her Ph.D. in organic chemistry from Purdue University and conducted postdoctoral research at The Scripps Research Institute on antiparasitic agents and DNA-encoded library technology.